nach oben

Erschienen in:

19.07.2019 | Original Article

Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene

verfasst von: Lina E. Aguirre, Georgia Colleluori, David Robbins, Richard Dorin, Vallabh O. Shah, Rui Chen, Irum Zeb Jan, Clifford Qualls, Dennis T. Villareal, Reina Armamento-Villareal

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the influence of single nucleotide polymorphisms (SNPs) of CYP19A1 on the response and susceptibility to side effects from testosterone therapy. This is a prospective, single-arm study of men with low-morning serum testosterone (<10.68 nmol/l) administered testosterone cypionate 200 mg intramuscularly every 2 weeks for 18 months.

Methods

We measured areal bone mineral density (aBMD) and body composition by dual energy X-ray absorptiometry, tibial volumetric BMD and geometry by peripheral quantitative computer tomography, bone turnover markers by enzyme-linked immunosorbent assay, testosterone, and estradiol by liquid-chromatography/mass-spectroscopy, genotyping by microarray, CYP19A1 expression by quantitative polymerase chain reaction, hematocrit and prostate-specific antigen (PSA).

Results

We enrolled 105 men (40–74-years-old). SNPs rs1062033 and rs700518 were associated with significant differences in outcomes at 18 months. The GG genotype in rs1062033 had significant increase in whole body aBMD, but had significant decrease in tibial bone size compared to the CG and CC genotypes. Body composition analysis showed that the CC genotype of rs1062033, and the AA genotype of rs700518, had significant increase in total lean and appendicular lean mass compared to CG and GG, and AG and GG, respectively. The GG genotype of rs700518 had significant increase in PSA (GG = 105.8 ± 23.3% vs. AG + AA = 53.4 ± 11.3%, p = 0.046) while hematocrit changes were comparable among genotypes. CYP19A1 expression was highest in GG genotype in both SNPs.

Conclusions

For the first time, we demonstrated that CYP19A1 SNPs influence response to testosterone therapy in hypogonadal men, highlighting the importance of genetic profiling in therapeutics even for common clinical conditions.

Nur mit Berechtigung zugänglich

N. Bassil, S. Alkaade, J.E. Morley, The benefits and risks of testosterone replacement therapy: a review. Ther. Clin. Risk Manag. 5(3), 427–448 (2009).PubMedPubMedCentral

P.J. Snyder, S. Bhasin, G.R. Cunningham, A.M. Matsumoto, A.J. Stephens-Shields, J.A. Cauley, T.M. Gill, E. Barrett-Connor, R.S. Swerdloff, C. Wang, K.E. Ensrud, C.E. Lewis, J.T. Farrar, D. Cella, R.C. Rosen, M. Pahor, J.P. Crandall, M.E. Molitch, D. Cifelli, D. Dougar, L. Fluharty, S.M. Resnick, T.W. Storer, S. Anton, S. Basaria, S.J. Diem, X. Hou, E.R. Mohler III, J.K. Parsons, N.K. Wenger, B. Zeldow, J.R. Landis, S.S. Ellenberg, Effects of testosterone treatment in older men. N. Engl. J. Med. 374(7), 611–624 (2016)CrossRefPubMedPubMedCentral

S. Basaria, A.S. Dobs, Hypogonadism and androgen replacement therapy in elderly men. Am. J. Med. 110(7), 563–572 (2001)CrossRefPubMed

P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, A. Dlewati, J. Staley, J. Santanna, S.C. Kapoor, M.F. Attie, J.G. Haddad Jr., B.L. Strom, Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84(6), 1966–1972 (1999)PubMed

J.A. Riancho, C. Sanudo, C. Valero, C. Pipaon, J.M. Olmos, V. Mijares, J.L. Fernandez-Luna, M.T. Zarrabeitia, Association of the aromatase gene alleles with BMD: epidemiological and functional evidence. J. Bone Miner. Res. 24(10), 1709–1718 (2009)CrossRefPubMed

N. Napoli, D.T. Villareal, S. Mumm, L. Halstead, S. Sheikh, M. Cagaanan, G.B. Rini, R. rmamento-Villareal, Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J. Bone Miner. Res. 20(2), 232–239 (2005)CrossRefPubMed

S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Fallon, Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86(8), 3555–3561 (2001)CrossRefPubMed

J.S. Finkelstein, H. Lee, B.Z. Leder, S.A. Burnett-Bowie, D.W. Goldstein, C.W. Hahn, S.C. Hirsch, A. Linker, N. Perros, A.B. Servais, A.P. Taylor, M.L. Webb, J.M. Youngner, E.W. Yu, Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J. Clin. Invest 126(3), 1114–1125 (2016)CrossRefPubMedPubMedCentral

C. Carani, K. Qin, M. Simoni, M. Faustini-Fustini, S. Serpente, J. Boyd, K.S. Korach, E.R. Simpson, Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337(2), 91–95 (1997)CrossRefPubMed

10.

E. Barrett-Connor, J.E. Mueller, D.G. von Muhlen, G.A. Laughlin, D.L. Schneider, D.J. Sartoris, Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 85(1), 219–223 (2000)PubMed

11.

L. Gennari, L. Masi, D. Merlotti, L. Picariello, A. Falchetti, A. Tanini, C. Mavilia, M.F. Del, S. Gonnelli, B. Lucani, C. Gennari, M.L. Brandi, A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J. Clin. Endocrinol. Metab. 89(6), 2803–2810 (2004)CrossRefPubMed

12.

J. Somner, S. McLellan, J. Cheung, Y.T. Mak, M.L. Frost, K.M. Knapp, A.S. Wierzbicki, M. Wheeler, I. Fogelman, S.H. Ralston, G.N. Hampson, Polymorphisms in the P450c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 89(1), 344–351 (2004)CrossRefPubMed

13.

J.A. Riancho, C. Valero, A. Naranjo, D.J. Morales, C. Sanudo, M.T. Zarrabeitia, Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 92(2), 660–665 (2007)CrossRefPubMed

14.

C.L. Tofteng, A. Kindmark, H. Brandstrom, B. Abrahamsen, S. Petersen, F. Stiger, L.S. Stilgren, J.E. Jensen, P. Vestergaard, B.L. Langdahl, L. Mosekilde, Polymorphisms in the CYP19 and AR genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcif. Tissue Int. 74(1), 25–34 (2004)CrossRefPubMed

15.

S. Bhasin, G.R. Cunningham, F.J. Hayes, A.M. Matsumoto, P.J. Snyder, R.S. Swerdloff, V.M. Montori, Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95(6), 2536–2559 (2010)CrossRefPubMed

16.

J.C.C. Kwong, Y. Krakowsky, E. Grober, Testosterone deficiency: a review and comparison of current guidelines. J. Sex. Med 16(6), 812–820 (2019). https://doi.org/10.1016/j.jsxm.2019.03.262 CrossRefPubMed

17.

J.P. Mulhall, L.W. Trost, R.E. Brannigan, E.G. Kurtz, J.B. Redmon, K.A. Chiles, D.J. Lightner, M.M. Miner, M.H. Murad, C.J. Nelson, E.A. Platz, L.V. Ramanathan, R.W. Lewis, Evaluation and management of testosterone deficiency: AUA Guideline. J. Urol. 200(2), 423–432 (2018). https://doi.org/10.1016/j.juro.2018.03.115 CrossRefPubMed

18.

G. Defeudis, R. Mazzilli, D. Gianfrilli, A. Lenzi, A.M. Isidori, The CATCH checklist to investigate adult-onset hypogonadism. Andrology 6(5), 665–679 (2018). https://doi.org/10.1111/andr.12506 CrossRefPubMed

19.

L.E. Aguirre, G. Colleluori, K.E. Fowler, I.Z. Jan, K. Villareal, C. Qualls, D. Robbins, D.T. Villareal, R. Armamento-Villareal, High aromatase activity in hypogonadal men is associated with higher spine bone mineral density, increased truncal fat and reduced lean mass. Eur. J. Endocrinol. 173(2), 167–174 (2015)CrossRefPubMed

20.

L.E. Aguirre, G. Colleluori, R. Dorin, D. Robbins, R. Chen, B. Jiang, C. Qualls, D.T. Villareal, R. Armamento-Villareal, Hypogonadal men with higher bodymass index have higher bone density and better bone quality but reduced muscle density. Calcif. Tissue Int. 101(6), 602–611 (2017).CrossRefPubMed

21.

S. Vandewalle, Y. Taes, T. Fiers, K. Toye, C.E. Van, I. Roggen, S.J. De, J.M. Kaufman, Associations of sex steroids with bone maturation, bone mineral density, bone geometry, and body composition: a cross-sectional study in healthy male adolescents. J. Clin. Endocrinol. Metab. 99(7), E1272–E1282 (2014)CrossRefPubMed

22.

H. Haapasalo, S. Kontulainen, H. Sievanen, P. Kannus, M. Jarvinen, I. Vuori, Exercise-induced bone gain is due to enlargement in bone size without a change in volumetric bone density: a peripheral quantitative computed tomography study of the upper arms of male tennis players. Bone 27(3), 351–357 (2000)CrossRefPubMed

23.

R. Armamento-Villareal, V.O. Shah, L.E. Aguirre, A.L. Meisner, C. Qualls, M.E. Royce, The rs4646 and rs12592697 polymorphisms in CYP19A1 are associated with disease progression among patients with breast cancer from different racial/ethnic backgrounds. Front Genet 7, 211 (2016). https://doi.org/10.3389/fgene.2016.00211 CrossRefPubMedPubMedCentral

24.

N. Napoli, A. Rastelli, C. Ma, J. Yarramaneni, S. Vattikutti, G. Moskowitz, T. Giri, C. Mueller, V. Kulkarny, C. Qualls, M. Ellis, R. Armamento-Villareal, Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER+breast cancer. Bone 55(2), 309–314 (2013)CrossRefPubMedPubMedCentral

25.

A.L. Eriksson, M. Lorentzon, L. Vandenput, F. Labrie, M. Lindersson, A.C. Syvanen, E.S. Orwoll, S.R. Cummings, J.M. Zmuda, O. Ljunggren, M.K. Karlsson, D. Mellstrom, C. Ohlsson, Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J. Clin. Endocrinol. Metab. 94(3), 1033–1041 (2009)CrossRefPubMed

26.

J.K. Amory, N.B. Watts, K.A. Easley, P.R. Sutton, B.D. Anawalt, A.M. Matsumoto, W.J. Bremner, J.L. Tenover, Exogenous testosterone or testosterone withfinasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89(2), 503–510 (2004).CrossRefPubMed

27.

B. Devlin, N. Risch, A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29, 311–322 (1995).CrossRefPubMed

28.

R.C. Lewontin, On measures of gametic disequilibrium. Genetics 120, 849–852 (1988).PubMedPubMedCentral

29.

R. Colomer, M. Monzo, I. Tusquets, J. Rifa, J.M. Baena, A. Barnadas, L. Calvo, F. Carabantes, C. Crespo, M. Munoz, A. Llombart, A. Plazaola, R. Artells, M. Gilabert, B. Lloveras, E. Alba, A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin. Cancer Res. 14(3), 811–816 (2008)CrossRefPubMed

30.

N. Napoli, A. Rastelli, C. Ma, G. Colleluori, S. Vattikuti, R. Armamento-Villareal, Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer. Pharm. Genom. 25(8), 377–381 (2015). https://doi.org/10.1097/FPC.0000000000000146 CrossRef

31.

J.S. Finkelstein, E.W. Yu, S.A. Burnett-Bowie, Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 369(25), 2457 (2013)CrossRefPubMed

32.

R. Armamento-Villareal, L. Aguirre, N. Napoli, K. Shah, T. Hilton, D.R. Sinacore, C. Qualls, D.T. Villareal, Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. Osteoporos. Int. 25(2), 551–558 (2014)

33.

T.G. Travison, S. Basaria, T.W. Storer, A.M. Jette, R. Miciek, W.R. Farwell, K. Choong, K. Lakshman, N.A. Mazer, A.D. Coviello, P.E. Knapp, J. Ulloor, A. Zhang, B. Brooks, A.H. Nguyen, R. Eder, N. LeBrasseur, A. Elmi, E. Appleman, L. Hede-Brierley, G. Bhasin, A. Bhatia, A. Lazzari, S. Davis, P. Ni, L. Collins, S. Bhasin, Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J. Gerontol. A Biol. Sci. Med. Sci. 66(10), 1090–1099 (2011)CrossRefPubMed

34.

G.K. Dimitriadis, H.S. Randeva, S. Aftab, A. Ali, J.G. Hattersley, S. Pandey, D.K. Grammatopoulos, G. Valsamakis, G. Mastorakos, T.H. Jones, T.M. Barber, Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine 60(1), 175–184 (2018). https://doi.org/10.1007/s12020-017-1516-x CrossRefPubMedPubMedCentral

35.

C.J. Gruber, W. Tschugguel, C. Schneeberger, J.C. Huber, Production and actions of estrogens. N. Engl. J. Med 346(5), 340–352 (2002). https://doi.org/10.1056/NEJMra000471 CrossRefPubMed

36.

M. Shozu, E.R. Simpson, Aromatase expression of human osteoblast-like cells. Mol. Cell Endocrinol. 139(1-2), 117–129 (1998)CrossRefPubMed

37.

A. Vottero, V. Rochira, M. Capelletti, I. Viani, L. Zirilli, T.M. Neri, C. Carani, S. Bernasconi, L. Ghizzoni, Aromatase is differentially expressed in peripheral blood leukocytes from children, and adult female and male subjects. Eur. J. Endocrinol. 154(3), 425–431 (2006). https://doi.org/10.1530/eje.1.02102 CrossRefPubMed

38.

Y. He, C.L. Wang, Effects of testosterone on PPARgamma and P450arom expression in polycystic ovary syndrome patients and related mechanisms. Eur. Rev. Med Pharm. Sci. 22(6), 1549–1553 (2018). https://doi.org/10.26355/eurrev_201803_14559 CrossRef

39.

S.J. Ellem, J.F. Schmitt, J.S. Pedersen, M. Frydenberg, G.P. Risbridger, Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab. 89(5), 2434–2441 (2004)CrossRefPubMed

40.

S.J. Ellem, H. Wang, M. Poutanen, G.P. Risbridger, Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am. J. Pathol. 175(3), 1187–1199 (2009)CrossRefPubMedPubMedCentral

41.

O. Cussenot, A.R. Azzouzi, N. Nicolaiew, G. Fromont, P. Mangin, L. Cormier, G. Fournier, A. Valeri, S. Larre, F. Thibault, J.P. Giordanella, M. Pouchard, Y. Zheng, F.C. Hamdy, A. Cox, G. Cancel-Tassin, Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol. 25(24), 3596–3602 (2007)CrossRefPubMed

42.

J. Beuten, J.A. Gelfond, J.L. Franke, K.S. Weldon, A.C. Crandall, T.L. Johnson-Pais, I.M. Thompson, R.J. Leach, Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol. Biomark. Prev. 18(6), 1869–1880 (2009)CrossRef

43.

L. Tang, M.E. Platek, S. Yao, C. Till, P.J. Goodman, C.M. Tangen, Y. Wu, E.A. Platz, M.L. Neuhouser, F.Z. Stanczyk, J.K.V. Reichardt, R.M. Santella, A. Hsing, W.D. Figg, S.M. Lippman, I.M. Thompson, C.B. Ambrosone, Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39(2), 125–133 (2018). https://doi.org/10.1093/carcin/bgx144 CrossRefPubMed

Titel: Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene
verfasst von: Lina E. Aguirre
Georgia Colleluori
David Robbins
Richard Dorin
Vallabh O. Shah
Rui Chen
Irum Zeb Jan
Clifford Qualls
Dennis T. Villareal
Reina Armamento-Villareal
Publikationsdatum: 19.07.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02008-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule l-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia

Death by unnatural causes, mainly suicide, is increased in patients with Hashimoto’s thyroiditis. A nationwide Danish register study

Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years

miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA

FGF21 and glycemic control in patients with T1D

Uremic leontiasis ossea

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin